RayKnowChina Research Map
Shortlist

Taiyuan

Shanxi Cancer Hospital

山西省肿瘤医院

Listed for 11 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanxi Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  2. Stomach cancer胃癌8 papers led
  3. Lung cancer肺癌21 papers led1 open trial led
  4. Pancreatic cancer胰腺癌1 paper led
  5. Breast cancer乳腺癌10 papers led
  6. Osteosarcoma骨肉瘤2 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Ewing sarcoma尤文肉瘤1 paper led
  9. Multiple myeloma多发性骨髓瘤0 papers led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  11. Lymphoma淋巴瘤2 papers led1 open trial led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 002025

3 hospitals in Taiyuan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyMolecular markers & genomics
Departments in papersRadiation oncologyGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led4
  1. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.2024Thoracic cancerFree full text
  2. Submucosal oesophageal squamous cell carcinoma with lymph node metastasis: a case report and literature review.2022BMC gastroenterologyFree full text
  3. MicroRNA-137 Inhibits Esophageal Squamous Cell Carcinoma by Downregulating DAAM1.2022Protein and peptide letters
  4. The Role of DBR1 as a Candidate Prognosis Biomarker in Esophageal Squamous Cell Carcinoma.2022Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Fat1 inhibits cell proliferation via ERK signaling pathway in esophageal squamous cell carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status8
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  5. SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingNCT05022654Study sitePhase 2Start 2021-12
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  7. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652Study siteStart 2018-10
  8. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 8 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 1120242025: 112025

1 hospital in Taiyuan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  3. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  5. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  6. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  8. Recruiting
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05687357

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan

  9. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryChemotherapy & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led8
  1. Prognostic value of c-MET protein expression in gastric cancer patients: a systematic review and meta-analysis.2025Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  2. LncRNA LINC01278 Regulates the Prognosis and Related Mechanisms of Gastric Cancer by Targeting miR-129-5p.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  3. CircRNA circSLIT2 is a novel diagnostic and prognostic biomarker for gastric cancer.2023Wiener klinische Wochenschrift
  4. Clinicopathological Significance and Molecular Mechanism of AKT/GSK3β Pathway-based Fibrillin-1 Expression in Gastric Cancer Progression.2022Cellular and molecular biology (Noisy-le-Grand, France)
  5. Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients.2022MedicineFree full text
  6. Ubiquitin-specific protease 1 overexpression indicates poor prognosis and promotes proliferation, migration, and invasion of gastric cancer cells.2022Tissue & cell
  7. Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.2021BMC cancerFree full text
  8. Hypoxia-Induced LXRα Contributes to the Migration and Invasion of Gastric Cancer Cells.2021Folia biologica
Chinese-language papers (not in the count)2
  1. [Effect of acupuncture on functional delayed gastric emptying after gastric cancer surgery based on enhance recovery after surgery].2023Zhongguo zhen jiu = Chinese acupuncture & moxibustionRCT
  2. [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status21
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingNCT07689851Study sitePhase 2Start 2026-07
  3. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  4. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  5. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  6. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  8. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Study sitePhase 2Start 2023-03
  9. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  10. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Study sitePhase 1Start 2024-12
  11. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Study sitePhase 2Start 2023-04
  12. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  13. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  14. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  15. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  17. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  18. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  19. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  20. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  21. Esophageal Cancer Genetics StudiesCompletedNCT00341276Study siteStart 1995-07

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 21 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.09%.

Papers led
21
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
39
led by another institution
Papers led per year
2021: 5520212022: 6620222023: 2220232024: 4420242025: 442025

4 hospitals in Taiyuan for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 40

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07486648

    Age 18 years to Not stated (registered criteria)

    Led by Shanxi Cancer Hospital; 1 listed hospital as study siteBeijing, Taiyuan

  2. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  3. Recruiting
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361497

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou

  4. Recruiting
    Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07361705

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shenyang, Taiyuan, Zhengzhou

  5. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  6. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  7. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  8. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  9. Recruiting
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07622186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou

  10. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  11. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  12. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  13. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  14. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  15. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  16. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  17. Recruiting
    A Study of SKB518 in Patients With Lung Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07019675

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou

  18. Recruiting
    Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
    Phase
    Phase 2/Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07100080

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Taiyuan, Wuhan

  19. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  20. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  21. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  22. Recruiting
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07190248

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  23. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  24. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  25. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  26. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  27. Recruiting
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06564324

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  28. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  29. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  30. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  31. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  32. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  33. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  34. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  35. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  36. Not yet recruiting
    Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07596524

    Age 1 year to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan

  37. Not yet recruiting
    A Phase 2 Study of ABSK043 Combined With Osimertinib
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07710612

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan

  38. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  39. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

  40. Enrolling by invitation
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04762459

    Age 18 years to 130 years (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologyENT / head & neck surgery

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led21
  1. Analysis on the hospitalization expenses structure and correlation degree of lung cancer: evidence from Shanxi Province, China.2025Frontiers in public healthFree full text
  2. Identification and validation of a diagnostic and prognostic model based on immune escape and cancer-associated fibroblast-related genes in lung adenocarcinoma.2025MedicineFree full text
  3. Construction and validation of an anoikis-related prognostic model for lung adenocarcinoma based on bulk and single-cell transcriptomic data.2025PloS oneFree full text
  4. Effect of defective H2B ubiquitination on the malignancy and repair of DNA double breaks and its significance in lung adenocarcinoma.2025Scientific reportsFree full text
  5. Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.2024BMC cancerFree full text
  6. Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer.2024Biotechnology & genetic engineering reviews
  7. Dabrafenib Inhibits Egr-1-Mediated Adhesion of Thyroid Cancer Cells to Pulmonary Microvascular Endothelium.2024Journal of biochemical and molecular toxicology
  8. Primary pulmonary alveolar soft part sarcoma with ASPSCR1-TFE3 gene fusion: Case report and literature review.2024MedicineFree full text
  9. Multi-scale dense selective network based on border modeling for lung nodule segmentation.2023International journal of computer assisted radiology and surgery
  10. Thyroid collision tumour with pulmonary metastases treated effectively with nedaplatin and paclitaxel chemotherapy: A case report.2023The Journal of international medical researchFree full text
  11. First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report.2022Annals of oncology : official journal of the European Society for Medical Oncology
  12. Causes of death following small cell lung cancer diagnosis: a population-based analysis.2022BMC pulmonary medicineFree full text
  13. Identification of a Novel circ_0010235/miR-1249-3p/HOXA13 Axis in Lung Adenocarcinoma.2022Biochemical genetics
  14. Farrerol exhibits inhibitory effects on lung adenocarcinoma cells by activating the mitochondrial apoptotic pathway.2022Journal of biochemical and molecular toxicology
  15. Prognostic Value of Geriatric Nutritional Risk Index for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.2022Lung
  16. Three-Dimensional Computed Tomography Bronchography and Angiography-Guided Thoracoscopic Segmentectomy for Pulmonary Nodules.2022Surgical innovation
  17. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.2021Annals of palliative medicine
  18. Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer.2021Annals of palliative medicine
  19. Effectiveness and postoperative pain level of single-port versus two-port thoracoscopic lobectomy for lung cancer: a retrospective cohort study.2021General thoracic and cardiovascular surgeryFree full text
  20. Effect of osimertinib in treating patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer and prognostic analysis.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  21. Circ_0074027 contributes to non-small cell lung cancer progression through positively modulating RHOA via sequestering miR-2467-3p.2021Journal of bioenergetics and biomembranes
Chinese-language papers (not in the count)3
  1. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status87
  1. Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingNCT07486648Lead sponsorPhase 1/Phase 2Start 2026-05
  2. Family-Supported Palliative Care in Advanced Lung CancerCompletedNCT07490639Lead sponsorN/AStart 2024-01
  3. MDT-Based Nursing for Small Cell Lung Cancer During Chemo-ImmunotherapyCompletedNCT07489339Lead sponsorN/AStart 2024-07
  4. Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung CancerCompletedNCT07498972Lead sponsorN/AStart 2023-01
  5. A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Study sitePhase 1/Phase 2Start 2026-02
  6. Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor TherapyNot yet recruitingNCT07596524Study siteStart 2026-07
  7. A Phase 2 Study of ABSK043 Combined With OsimertinibNot yet recruitingNCT07710612Study sitePhase 2Start 2026-08
  8. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingNCT07361497Study sitePhase 3Start 2026-03
  9. A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Study sitePhase 2Start 2026-07
  10. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingNCT07472517Study sitePhase 3Start 2026-04
  11. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  12. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  13. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingNCT07554339Study sitePhase 3Start 2026-06
  14. Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionRecruitingNCT07361705Study sitePhase 1Start 2026-01
  15. Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Study sitePhase 3Start 2025-04
  16. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  17. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Study siteStart 2025-04
  18. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingNCT07100080Study sitePhase 2/Phase 3Start 2025-11
  19. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Study sitePhase 3Start 2025-04
  20. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  21. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  22. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingNCT06712355Study sitePhase 3Start 2025-02
  23. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Study sitePhase 1/Phase 2Start 2025-09
  24. A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingNCT07190248Study sitePhase 3Start 2025-10
  25. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Study sitePhase 3Start 2025-10
  26. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Study sitePhase 3Start 2025-06
  27. A Study of SKB518 in Patients With Lung CancerRecruitingNCT07019675Study sitePhase 2Start 2025-08
  28. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Study sitePhase 3Start 2024-10
  29. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  30. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  31. A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingNCT06564324Study sitePhase 3Start 2024-11
  32. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  33. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingNCT06416410Study sitePhase 3Start 2024-08
  34. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Study sitePhase 3Start 2023-11
  35. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Study sitePhase 3Start 2023-11
  36. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Study sitePhase 3Start 2023-11
  37. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  38. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Study sitePhase 2Start 2023-06
  39. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  40. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Study sitePhase 1/Phase 2Start 2022-12
  41. Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Study sitePhase 3Start 2021-08
  42. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  43. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Study sitePhase 2/Phase 3Start 2020-12
  44. Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Study sitePhase 3Start 2025-11
  45. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Study sitePhase 2Start 2025-04
  46. A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06623136Study sitePhase 2Start 2025-04
  47. A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Study sitePhase 3Start 2025-08
  48. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT07005336Study sitePhase 2Start 2025-01
  49. Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)Active, not recruitingNCT06117774Study sitePhase 3Start 2024-02
  50. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Study sitePhase 3Start 2024-06
  51. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Study sitePhase 3Start 2024-10
  52. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Study sitePhase 3Start 2024-06
  53. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Study sitePhase 3Start 2024-06
  54. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Study sitePhase 1Start 2024-12
  55. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Study sitePhase 3Start 2023-10
  56. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryCompletedNCT05872763Study siteStart 2023-08
  57. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedNCT05635708Study sitePhase 2Start 2023-02
  58. A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLCActive, not recruitingNCT06443684Study siteStart 2023-05
  59. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Active, not recruitingNCT05816252Study sitePhase 2Start 2023-04
  60. A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedNCT06029127Study sitePhase 2Start 2023-10
  61. A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Study sitePhase 3Start 2023-02
  62. Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Study sitePhase 1Start 2023-11
  63. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Status unknownNCT05922345Study sitePhase 3Start 2023-06
  64. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Study sitePhase 3Start 2023-05
  65. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Study sitePhase 2Start 2023-04
  66. Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664Study siteStart 2022-09
  67. Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC PatientsStatus unknownNCT05443646Study sitePhase 2Start 2022-09
  68. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  69. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerStatus unknownNCT05042375Study sitePhase 3Start 2022-09
  70. Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15CompletedNCT05546476Study sitePhase 2Start 2022-11
  71. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Study sitePhase 2Start 2022-05
  72. Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Study sitePhase 3Start 2022-05
  73. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Study sitePhase 3Start 2022-05
  74. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Study sitePhase 2Start 2022-06
  75. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Study sitePhase 2Start 2021-07
  76. A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04513925Study sitePhase 3Start 2020-08
  77. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Study siteStart 2020-07
  78. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  79. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Study sitePhase 3Start 2020-09
  80. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Study sitePhase 3Start 2020-05
  81. Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Study sitePhase 1Start 2020-06
  82. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  83. Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03986528Study sitePhase 4Start 2019-08
  84. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07
  85. Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFRStatus unknownNCT05767866Study sitePhase 1/Phase 2Start 2018-03
  86. Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownNCT02103257Study sitePhase 4Start 2014-03
  87. Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Study sitePhase 2Start 2014-08

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 1 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.02%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Taiyuan for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07640295

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07823049

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yangzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 10 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.06%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
18
led by another institution
Papers led per year
2021: 5520212022: 0020222023: 4420232024: 0020242025: 112025

3 hospitals in Taiyuan for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 18

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  3. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  4. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  5. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  6. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  7. Recruiting
    A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07010939

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  8. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  9. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  10. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  11. Recruiting
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07173751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesHefei, Jinan, Lanzhou, Linyi, Nanchang, Taiyuan, Wuhan, Xi'an, Zhengzhou

  12. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  13. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  14. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  15. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  16. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  17. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  18. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led10
  1. Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021.2025BMC cancerFree full text
  2. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.2023Advances in therapy
  3. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.2023Advances in therapyFree full text
  4. Clinical features and prognostic factors of breast cancer in young women: a retrospective single-center study.2023Archives of gynecology and obstetrics
  5. Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple Cancers.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  6. Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C.2021BioengineeredFree full text
  7. Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review.2021Diagnostic pathologyFree full text
  8. Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis.2021Molecular medicine reportsFree full text
  9. Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.2021Oncology reports
  10. Knockdown of TRIM66 in MDA-MB-468 triple negative breast cancer cell line suppresses proliferation and promotes apoptosis through EGFR signaling.2021Polish journal of pathology : official journal of the Polish Society of Pathologists
Chinese-language papers (not in the count)2
  1. [Encapsulated apocrine papillary carcinoma of the breast: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].2021Zhonghua fu chan ke za zhi
All its trials on ClinicalTrials.gov, any status33
  1. A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT07347600Study siteStart 2026-01
  2. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)RecruitingNCT07876557Study sitePhase 2Start 2026-10
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Study sitePhase 3Start 2025-03
  4. A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitationNCT07376629Study sitePhase 2Start 2025-08
  5. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Study sitePhase 3Start 2025-09
  6. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Study sitePhase 3Start 2025-07
  7. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingNCT07173751Study sitePhase 3Start 2025-10
  8. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Study sitePhase 2/Phase 3Start 2025-06
  9. A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingNCT07003074Study sitePhase 3Start 2025-06
  10. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Study sitePhase 1/Phase 2Start 2025-09
  11. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07673029Study sitePhase 3Start 2025-01
  12. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingNCT06926868Study sitePhase 2/Phase 3Start 2025-09
  13. A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer PatientsRecruitingNCT07010939Study siteStart 2025-04
  14. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776Study siteStart 2024-01
  15. Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)RecruitingNCT06682195Study sitePhase 2Start 2024-10
  16. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  17. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingNCT06079983Study sitePhase 3Start 2023-12
  18. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Study sitePhase 1/Phase 2Start 2022-12
  19. Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerTerminatedNCT06851442Study sitePhase 1/Phase 2Start 2025-05
  20. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Study sitePhase 3Start 2024-06
  21. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerCompletedNCT05945927Study siteStart 2023-09
  22. A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast CancerCompletedNCT06115902Study sitePhase 1Start 2023-11
  23. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Study sitePhase 3Start 2023-12
  24. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownNCT05755048Study sitePhase 3Start 2023-03
  25. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  26. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  27. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedNCT04927481Study sitePhase 2Start 2021-06
  28. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  29. A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Study sitePhase 3Start 2020-06
  30. A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerCompletedNCT03371017Study sitePhase 3Start 2018-01
  31. The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownNCT04185649Study sitePhase 3Start 2018-07
  32. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesStatus unknownNCT03500380Study sitePhase 2/Phase 3Start 2018-04
  33. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Study sitePhase 3Start 2012-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

5 hospitals in Taiyuan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

2 hospitals in Taiyuan for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Rectal adenocarcinoma coexisting with metastatic small intestinal stromal tumor: case report and literature review].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Taiyuan for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

4 hospitals in Taiyuan for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taiyuan for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Lead sponsorPhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 2 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.05%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
18
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Taiyuan for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 19

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06255704

    Age 18 years to 70 years (registered criteria)

    Led by Shanxi Cancer HospitalTaiyuan

  2. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07496229

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  4. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  5. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  6. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  7. Recruiting
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07059650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07124936

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou

  9. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  10. Recruiting
    A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06219356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou

  11. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  12. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  13. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  15. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  16. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  17. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  18. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  19. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led2
  1. Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with lymphoma.2021Annals of palliative medicine
  2. Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma.2021MedicineFree full text
Chinese-language papers (not in the count)4
  1. [Prognostic Value of Baseline 18F-FDG PET/CT Combined with Clinicopathological Characteristics in Diffuse Large B-Cell Lymphoma].2025Zhongguo shi yan xue ye xue za zhi
  2. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma].2022Zhongguo shi yan xue ye xue za zhi
  3. [Expression of GATA3 and bcl-11b in peripheral T-cell lymphoma and their clinical significance].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Research progress on prognostic factors of extranodal NK/T-cell lymphoma].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status35
  1. A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma PatientsNot yet recruitingNCT06255704Lead sponsorPhase 2Start 2024-03
  2. Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell LymphomaStatus unknownNCT04715217Lead sponsorPhase 1/Phase 2Start 2021-01
  3. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Study sitePhase 3Start 2026-03
  4. Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)RecruitingNCT07496229Study sitePhase 1/Phase 2Start 2026-04
  5. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingNCT07896590Study sitePhase 3Start 2026-10
  6. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Study sitePhase 3Start 2025-01
  7. A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Study sitePhase 2Start 2025-11
  8. Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaNot yet recruitingNCT07187960Study sitePhase 3Start 2025-11
  9. DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)RecruitingNCT07059650Study sitePhase 1/Phase 2Start 2025-08
  10. A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaRecruitingNCT07124936Study sitePhase 1/Phase 2Start 2025-07
  11. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingNCT06829771Study sitePhase 1/Phase 2Start 2025-04
  12. Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Study sitePhase 2Start 2025-03
  13. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Study sitePhase 2/Phase 3Start 2024-05
  14. A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Study sitePhase 2Start 2024-11
  15. A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin LymphomasRecruitingNCT06219356Study sitePhase 1Start 2024-01
  16. A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingNCT07234162Study sitePhase 3Start 2024-05
  17. A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Study sitePhase 3Start 2024-05
  18. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Study sitePhase 3Start 2023-12
  19. Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Study sitePhase 1/Phase 2Start 2022-05
  20. Evaluate the Safety and Clinical Activity of HH2853RecruitingNCT04390737Study sitePhase 1/Phase 2Start 2020-09
  21. A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingNCT05624554Study sitePhase 3Start 2023-03
  22. A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell LymphomaActive, not recruitingNCT05954910Study siteStart 2023-08
  23. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Study sitePhase 3Start 2023-02
  24. Evaluating Different Doses of Orelabrutinib in MCLCompletedNCT05978739Study sitePhase 2Start 2023-08
  25. A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaActive, not recruitingNCT07226752Study sitePhase 3Start 2022-10
  26. A Study of Chinese Adults With LymphomaCompletedNCT05288491Study siteStart 2022-10
  27. AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)CompletedNCT06511869Study sitePhase 2Start 2022-03
  28. Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT05471843Study sitePhase 1/Phase 2Start 2022-09
  29. A Study of CS5001 in Patients With Advanced Solid Tumors and LymphomasSuspendedNCT05279300Study sitePhase 1Start 2022-03
  30. A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Study sitePhase 3Start 2022-03
  31. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Study sitePhase 2Start 2021-08
  32. A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)Status unknownNCT04324879Study sitePhase 2Start 2020-05
  33. Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeStatus unknownNCT02560441Study sitePhase 2Start 2015-09
  34. R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Study sitePhase 3Start 2013-05
  35. An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular LymphomaCompletedNCT01340443Study siteStart 2011-01

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山西省肿瘤医院

Shanxi Cancer Hospital

太原

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data